Erik Magnus Ohman, MBBS

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 8678A Hafs Bldg, Durham, NC 27710
Phone (919) 681-2069
Email address ohman001@mc.duke.edu

Dr. Ohman, Professor of Medicine, received medical degrees from the Royal College of Surgeons in Ireland and the National University of Ireland (1984, Fellowship 1984-1987), and completed his training in cardiology at Duke University (1987-1991), where he has remained on faculty. In 2001, he became Chief of Cardiology at the University of North Carolina at Chapel Hill, where he founded the UNC Heart Center and became its first director. In 2005 he returned to Duke to pursue his interest in advanced coronary disease as the Director of the Program for Advanced Coronary Disease. Since that time, he has been appointed to Associate Director of the Duke Heart Center, the Kent and Siri Rawson Director for the Program for Advanced Coronary Disease, and most recently, Vice-Chair of Development and Innovation in the Department of Medicine.

Dr. Ohman’s clinical and research interests include interventional cardiology and high-risk supported PCI, and treatment of patients with advanced/complex coronary disease. He has researched how to improve patient care through the use of guidelines-based therapies and adherence, and examining global cardiovascular risk and health. He has been a participant on numerous guidelines writing committees, served on the ACC/AHA oversight committee for guidelines development, and has served on the steering committees for trials on ST-elevation myocardial infarction and non-ST-elevation ACS. He is a consultant to the National Institutes of Health, and a consultant for the FDA Advisory Panel for Cardiovascular Devices. 

Dr. Ohman has published over 600 peer-reviewed papers and three books in cardiovascular medicine. He holds three U.S. patents in reperfusion therapy. He is an associate editor for the American Heart Journal and serves on the editorial boards of the Journal of the American College of Cardiology and the American Journal of Cardiology.  He is a Fellow of the Royal College of Physicians in Ireland, the Royal Society of Medicine (U.K.), the European Society of Cardiology, the Society of Cardiac Angiography and Interventions, and the American College of Cardiology. 

Education and Training

  • M.B.B.S., Royal College of Surgeons (Ireland), 1981

Publications

Ohman, E. M., R. A. Harrington, A. M. Lincoff, M. M. Kitt, N. S. Kleiman, and J. E. Tcheng. “Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor..” Eur Heart J 16 Suppl L (November 1995): 50–55. https://doi.org/10.1093/eurheartj/16.suppl_l.50.

PMID
8869019
Full Text

Newby, L. K., W. B. Gibler, E. M. Ohman, and R. H. Christenson. “Biochemical markers in suspected acute myocardial infarction: the need for early assessment..” Clin Chem 41, no. 9 (September 1995): 1263–65.

PMID
7656436
Scholars@Duke

Pilote, L., R. M. Califf, S. Sapp, D. P. Miller, D. B. Mark, W. D. Weaver, J. M. Gore, P. W. Armstrong, E. M. Ohman, and E. J. Topol. “Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..” N Engl J Med 333, no. 9 (August 31, 1995): 565–72. https://doi.org/10.1056/NEJM199508313330907.

PMID
7623907
Full Text

Davenport, R. J., M. S. Dennis, P. A. Sandercock, C. P. Warlow, I. R. Starkey, C. V. Ruckley, J. M. Porter, G. Jackson, E. M. Ohman, and P. Hornick. “How should a patient presenting with unstable angina and a recent stroke be managed?.” Bmj 310, no. 6992 (June 3, 1995): 1449–52. https://doi.org/10.1136/bmj.310.6992.1449a.

PMID
7613280
Full Text

Christenson, R. H., E. M. Ohman, E. J. Topol, M. A. O’Hanesian, K. N. Sigmon, S. H. Duh, D. Kereiakes, S. J. Worley, B. S. George, and C. K. Pizzo. “Creatine kinase MM and MB isoforms in patients receiving thrombolytic therapy and acute angiography. TAMI Study Group..” Clin Chem 41, no. 6 Pt 1 (June 1995): 844–52.

PMID
7768002
Scholars@Duke

Harrington, R. A., A. M. Lincoff, R. M. Califf, D. R. Holmes, L. G. Berdan, M. A. O’Hanesian, G. P. Keeler, K. N. Garratt, E. M. Ohman, and D. B. Mark. “Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT)..” J Am Coll Cardiol 25, no. 7 (June 1995): 1693–99.

PMID
7759725
Scholars@Duke

Lincoff, A. M., E. J. Topol, R. M. Califf, K. N. Sigmon, K. L. Lee, E. M. Ohman, U. Rosenschein, and S. G. Ellis. “Significance of a coronary artery with Thrombolysis in Myocardial infarction grade 2 flow "patency" (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials).” The American Journal of Cardiology 75, no. 14 (May 1, 1995): 871–76. https://doi.org/10.1016/S0002-9149(99)80678-X.

Full Text

Lincoff, A. M., E. J. Topol, R. M. Califf, K. N. Sigmon, K. L. Lee, E. M. Ohman, U. Rosenschein, and S. G. Ellis. “Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group..” Am J Cardiol 75, no. 14 (May 1, 1995): 871–76.

PMID
7732992
Scholars@Duke

Pages